



MASSACHUSETTS

Blue Cross Blue Shield of Massachusetts is an Independent Licensee of the Blue Cross and Blue Shield Association

## Medical Policy

# Spinal Cord and Dorsal Root Ganglion Stimulation

### Table of Contents

- [Policy: Commercial](#)
- [Policy: Medicare](#)
- [Authorization Information](#)
- [Coding Information](#)
- [Description](#)
- [Policy History](#)
- [Information Pertaining to All Policies](#)
- [References](#)

### Policy Number: 472

BCBSA Reference Number: 7.01.25

NCD/LCD: National Coverage Determination (NCD) for Electrical Nerve Stimulators (160.7)

### Related Policies

Deep Brain Stimulation, [#473](#)

### Policy

#### Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity

Spinal cord stimulation with standard or high-frequency stimulation may be considered **MEDICALLY NECESSARY** for treatment of severe and chronic pain of the trunk or limbs that is refractory to all other pain therapies when ALL of the following patient criteria are met:

- The treatment is used only as a last resort; other treatment modalities (pharmacologic, surgical, psychological, physical, if applicable) have failed or are judged to be unsuitable or contraindicated;
- Pain is neuropathic in nature (ie, resulting from actual damage to the peripheral nerves). Common indications include, but are not limited to, failed back surgery syndrome, complex regional pain syndrome (ie, reflex sympathetic dystrophy), arachnoiditis, radiculopathies, phantom limb/stump pain, and peripheral neuropathy. Spinal cord stimulation is generally not effective in treating nociceptive pain (resulting from irritation, not damage to the nerves) and central deafferentation pain (related to central nervous system damage from a stroke or spinal cord injury).
- No serious untreated drug habituation exists;
- Demonstration of at least 50% pain relief with a temporarily implanted electrode precedes permanent implantation;
- All the facilities, equipment, and professional and support personnel required for the proper diagnosis, treatment, and follow-up of the patient are available.

Dorsal root ganglion neurostimulation is considered **MEDICALLY NECESSARY** for the treatment of severe and chronic pain of the trunk or limbs that is refractory to all other pain therapies when ALL of the following patient criteria are met:

- The treatment is used only as a last resort; other treatment modalities (pharmacologic, surgical, psychological, physical, if applicable) have failed or are judged to be unsuitable or contraindicated;

- Pain is neuropathic in nature (ie, resulting from actual damage to the peripheral nerves). Common indications include, but are not limited to, failed back surgery syndrome, complex regional pain syndrome (ie, reflex sympathetic dystrophy), arachnoiditis, radiculopathies, phantom limb/stump pain, and peripheral neuropathy. Spinal cord stimulation is generally not effective in treating nociceptive pain (resulting from irritation, not damage to the nerves) and central deafferentation pain (related to central nervous system damage from a stroke or spinal cord injury).
- No serious untreated drug habituation exists;
- Demonstration of at least 50% pain relief with a temporarily implanted electrode precedes permanent implantation;
- All the facilities, equipment, and professional and support personnel required for the proper diagnosis, treatment, and follow-up of the patient are available.

Spinal cord stimulation is considered **INVESTIGATIONAL** in all other situations including, but not limited to, treatment of critical limb ischemia to forestall amputation and treatment of refractory angina pectoris, heart failure, and cancer-related pain.

## Medicare HMO Blue<sup>SM</sup> and Medicare PPO Blue<sup>SM</sup> Members

Medical necessity criteria and coding guidance can be found through the link below.

[National Coverage Determinations \(NCDs\)](#)

National Coverage Determination (NCD) for Electrical Nerve Stimulators (160.7)

**Note:** To review the specific NCD, please remember to click “accept” on the CMS licensing agreement at the bottom of the CMS webpage.

### Prior Authorization Information

#### Inpatient

- For services described in this policy, precertification/preauthorization **IS REQUIRED** for all products if the procedure is performed **inpatient**.

#### Outpatient

- For services described in this policy, see below for products where prior authorization **might be required** if the procedure is performed **outpatient**.

	Outpatient
Commercial Managed Care (HMO and POS)	Prior authorization is <b>required</b> .
Commercial PPO and Indemnity	Prior authorization is <b>not required</b> .
Medicare HMO Blue <sup>SM</sup>	Prior authorization is <b>required</b> .
Medicare PPO Blue <sup>SM</sup>	Prior authorization is <b>not required</b> .

**Note:** For Commercial Managed Care (HMO and POS) and Medicare HMO Blue<sup>SM</sup>, the temporary implanted electrode (CPT code 63650) that precedes permanent implantation does not require prior authorization. However, prior authorization is required for the permanent placement of implanted electrodes (CPT codes 63655 and 63685).

### CPT Codes / HCPCS Codes / ICD Codes

*Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.*

*Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.*

*The following codes are included below for informational purposes only; this is not an all-inclusive list.*

The above **medical necessity criteria** **MUST** be met for the following codes to be covered for Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity:

### CPT Codes

CPT codes:	Code Description
63650	Percutaneous implantation of neurostimulator electrode array; epidural
63655	Laminectomy for implantation of neurostimulator electrode plate/paddle; epidural
63685	Insertion or replacement of spinal neurostimulator pulse generator or receiver, direct or inductive coupling

### HCPCS Codes

HCPCS codes:	Code Description
C1822	Generator, neurostimulator (implantable), high frequency, with rechargeable battery and charging system

The following ICD Diagnosis Codes are considered medically necessary when submitted with the CPT and HCPCS codes above if **medical necessity criteria** are met:

### ICD-10 Diagnosis Codes

ICD-10-CM Diagnosis codes:	Code Description
G03.9	Meningitis, unspecified
G56.40	Causalgia of unspecified upper limb
G56.41	Causalgia of right upper limb
G56.42	Causalgia of left upper limb
G57.70	Causalgia of unspecified lower limb
G57.71	Causalgia of right lower limb
G57.72	Causalgia of left lower limb
G60.3	Idiopathic progressive neuropathy
G60.8	Other hereditary and idiopathic neuropathies
G60.9	Hereditary and idiopathic neuropathy, unspecified
G62.89	Other specified polyneuropathies
G62.9	Polyneuropathy, unspecified
G89.21	Chronic pain due to trauma
G89.22	Chronic post-thoracotomy pain
G89.28	Other chronic postprocedural pain
G89.29	Other chronic pain
G89.3	Neoplasm related pain (acute) (chronic)
G89.4	Chronic pain syndrome
G90.511	Complex regional pain syndrome I of right upper limb
G90.512	Complex regional pain syndrome I of left upper limb
G90.513	Complex regional pain syndrome I of upper limb, bilateral
G90.519	Complex regional pain syndrome I of unspecified upper limb
G90.521	Complex regional pain syndrome I of right lower limb
G90.522	Complex regional pain syndrome I of left lower limb
G90.523	Complex regional pain syndrome I of lower limb, bilateral
G90.529	Complex regional pain syndrome I of unspecified lower limb
G90.59	Complex regional pain syndrome I of other specified site
M54.10	Radiculopathy, Site Unspecified

M54.11	Radiculopathy, occipito-atlanto-axial region
M54.12	Radiculopathy, cervical region
M54.13	Radiculopathy, cervicothoracic region
M54.14	Radiculopathy, thoracic region
M54.15	Radiculopathy, thoracolumbar region
M54.16	Radiculopathy, lumbar region
M54.17	Radiculopathy, lumbosacral region
M54.18	Radiculopathy, sacral and sacrococcygeal region
M79.2	Neuralgia And Neuritis, Unspecified
M96.1	Postlaminectomy syndrome, not elsewhere classified

## Description

### Chronic Pain

Spinal cord stimulation has been used in a wide variety of chronic refractory pain conditions, including pain associated with cancer, failed back pain syndromes, arachnoiditis, and complex regional pain syndrome (ie, chronic reflex sympathetic dystrophy). There has also been interest in spinal cord stimulation as a treatment of critical limb ischemia, primarily in patients who are poor candidates for revascularization and in patients with refractory chest pain.

### Spinal Cord Stimulation

Spinal cord stimulation (also called dorsal column stimulation) involves the use of low-level epidural electrical stimulation of the spinal cord dorsal columns. The neurophysiology of pain relief after spinal cord stimulation is uncertain but may be related to either activation of an inhibitory system or blockage of facilitative circuits.

Spinal cord stimulation devices consist of several components: (1) the lead that delivers the electrical stimulation to the spinal cord; (2) an extension wire that conducts the electrical stimulation from the power source to the lead; and (3) a power source that generates the electricity. The lead may incorporate from 4 to 8 electrodes, with 8 electrodes more commonly used for complex pain patterns. There are 2 basic types of power source: one type, the power source (battery), can be surgically implanted or worn externally with an antenna over the receiver; the other, a radiofrequency receiver, is implanted. Totally implantable systems are most commonly used.

The patient's pain distribution pattern dictates at what level of the spinal cord the stimulation lead is placed. The pain pattern may influence the type of device used. For example, a lead with 8 electrodes may be selected for those with complex pain patterns or bilateral pain. Implantation of the spinal cord stimulator is typically a 2-step process. Initially, the electrode is temporarily implanted in the epidural space, allowing a trial period of stimulation. Once treatment effectiveness is confirmed (defined as at least 50% reduction in pain), the electrodes and radio-receiver/transducer are permanently implanted. Successful spinal cord stimulation may require extensive programming of the neurostimulators to identify the optimal electrode combinations and stimulation channels.

Traditional spinal cord stimulation devices use electrical stimulation with a frequency of 100 to 1000 Hz. In 2015, a spinal cord stimulation device, using a higher frequency (10,000 Hz) than predicate devices, was approved by the U.S. Food and Drug Administration (FDA) through the premarket approval process. High-frequency stimulation is proposed to be associated with fewer paresthesias, which are a recognized effect of spinal cord stimulation. In 2016, the FDA approved a clinician programmer application that allows a spinal cord stimulation device to provide stimulation in bursts rather than at a constant rate. Burst stimulation is proposed to relieve pain with fewer paresthesias. The burst stimulation device works in conjunction with standard spinal cord stimulation devices. With the newly approved app, stimulation is provided in five, 500-Hz burst spikes at a rate of 40 Hz, with a pulse width of 1 ms.

The incidence of adverse events related to spinal cord stimulation have been reported to occur in 30% to 40% of cases.<sup>1</sup> Adverse events can either be hardware-related or biological. Hardware-related complications include lead migration or lead failure or fracture. Biological complications include infection

and pain. More severe biological complications are rare, including dural puncture headache (estimated incidence, up to 0.3%) and neurological damage (estimated incidence, 0.25%).

Other neurostimulators target the dorsal root ganglion. Dorsal root ganglia consist of sensory cell bodies that transmit input from the peripheral nervous system to the central nervous system and play a role in neuropathic pain perception. Dorsal root ganglia are located in the epidural space between spinal nerves and the spinal cord on the posterior root in a minimal amount of cerebrospinal fluid, amenable to epidural access. Two systems targeting the dorsal root ganglion have received approval or clearance from the FDA.

A retrospective analysis of the FDA's Manufacturer and User Facility Device Experience (MAUDE) database provided information on complications related to the use of dorsal root ganglion stimulation.<sup>2</sup> The MAUDE database was queried for dorsal root ganglion stimulation reports through 2017, identifying 979 episodes. Complications were predominantly device-related (47%; lead migration and lead damage), with the remaining comprised of procedural complications (28%; infection, new neurologic symptoms, and dural puncture), patient complaints (12%; site pain and unwanted stimulation), serious adverse events (2.4%), and "other" complications (4.6%). The prevalence of complications cannot be estimated using the MAUDE database; while facilities are mandated to report events, patients and health care providers may report events but are not mandated to do so.

## Summary

Spinal cord stimulation delivers low-voltage electrical stimulation to the dorsal columns of the spinal cord to block the sensation of pain; this is achieved through a surgically implanted spinal cord stimulation device, which comes equipped with a radiofrequency receiver. The neurostimulator device is also issued with a standard power source (battery) that can be implanted or worn externally. Other neurostimulators target the dorsal root ganglion.

### Treatment-Refractory Chronic Pain

For individuals who have treatment-refractory chronic pain of the trunk or limbs who receive standard spinal cord stimulation, the evidence includes systematic reviews and randomized controlled trials (RCTs). Relevant outcomes are symptoms, functional outcomes, quality of life, medication use, and treatment-related morbidity. Available RCTs are heterogeneous regarding underlying diagnoses in select patient populations. However, the trials including patients with underlying neuropathic pain processes have shown a significant benefit with spinal cord stimulation. Systematic reviews have supported the use of spinal cord stimulation to treat refractory trunk or limb pain, and patients who have failed all other treatment modalities have few options. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have treatment-refractory chronic pain of the trunk or limbs who receive high-frequency spinal cord stimulation, the evidence includes 3 RCTs. Relevant outcomes are symptoms, functional outcomes, quality of life, medication use, and treatment-related morbidity. One RCT comparing high-frequency with standard spinal cord stimulation in patients who had not previously been treated with spinal cord stimulation found a clinically and statistically significant benefit associated with high-frequency spinal cord stimulation. Another RCT in patients who had chronic pain despite previous treatment with standard spinal cord stimulation found no benefit for those receiving high-frequency stimulation compared with sham-control; however, it is difficult to compare these findings with other trials of spinal cord stimulation due to the different patient populations, short treatment periods, and the crossover period effect. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have treatment-refractory chronic pain of the trunk or limbs who receive dorsal root ganglion neurostimulation, the evidence includes an RCT and many case series. Relevant outcomes are symptoms, functional outcomes, quality of life, medication use, and treatment-related morbidity. The unblinded RCT found that patients receiving dorsal root ganglion neurostimulation had significantly higher rates of treatment success (physical functioning score and quality of life measures), at 3 and 12 months compared with those receiving standard spinal cord stimulation devices. Dorsal root ganglion neurostimulation was found to be noninferior to spinal cord stimulation in percentage achieving  $\geq 50\%$

pain reduction, emotional functioning score, and 36-Item Short-Form Health Survey scores. Both groups experienced paresthesias but patients in the dorsal root ganglion group reported less postural variation in paresthesia and reduced extraneous stimulation in nonpainful areas. Rates of serious adverse events were similar between the 2 study arms. While most of the case series were small (sample sizes ranged from 10 to 65), all reported results that were consistent with the RCT results. The largest case series had the longest follow-up, reporting continued improvements in pain and psychological scores through 3 years. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

### **Critical Limb Ischemia**

For individuals who have critical limb ischemia who receive spinal cord stimulation, the evidence includes several small RCTs. Relevant outcomes are overall survival, symptoms, functional outcomes, quality of life, morbid events, hospitalizations, and treatment-related morbidity. In some pooled analyses of these RCTs, spinal cord stimulation did not result in a significantly lower rate of amputation, although one meta-analysis that included a nonrandomized study reported a significant difference. The evidence is insufficient to determine the effects of the technology on health outcomes.

### **Treatment-Refractory Angina Pectoris**

For individuals who have treatment-refractory angina pectoris who receive spinal cord stimulation, the evidence includes RCTs. Relevant outcomes are overall survival, symptoms, functional outcomes, quality of life, morbid events, hospitalizations, and treatment-related morbidity. Numerous small RCTs have evaluated spinal cord stimulation as a treatment for refractory angina. While some have reported benefits, most have not. In 2 recent RCTs, there was no significant benefit in the primary outcomes. The evidence is insufficient to determine the effects of the technology on health outcomes.

### **Heart Failure**

For individuals who have heart failure who receive spinal cord stimulation, the evidence includes RCTs. Relevant outcomes are overall survival, symptoms, functional outcomes, quality of life, morbid events, hospitalizations, and treatment (n=66) did not find significant differences between groups but might have been underpowered to do so. The evidence is insufficient to determine the effects of the technology on health outcomes.

### **Cancer-Related Pain**

For individuals who have cancer-related pain who receive spinal cord stimulation, the evidence includes case series. Relevant outcomes are symptoms, functional outcomes, medication use, and treatment-related morbidity. No RCTs evaluating spinal cord stimulation in this population were identified. The evidence is insufficient to determine the effects of the technology on health outcomes.

## **Policy History**

<b>Date</b>	<b>Action</b>
6/2020	BCBSA National medical policy review. Description, summary and references updated. Policy statements unchanged.
9/2019	BCBSA National medical policy review. New medically necessary indications described. Dorsal root ganglion neurostimulation is considered medically necessary for the treatment of severe and chronic pain of the trunk or limbs. Clarified coding information. Effective 9/1/2019.
1/2019	Clarified coding information.
6/2018	BCBSA National medical policy review. Policy clarified to include burst neurostimulation as an alternate programming of a standard SCS device.
3/2018	Clarified coding information.
12/2017	BCBSA National medical policy review. "Wireless injectable" removed from policy statement on dorsal root ganglion neurostimulation. "Dorsal root ganglion" added to policy title. Effective 12/1/2017.
6/2017	BCBSA National medical policy review. New medically necessary and investigational indications described. Effective 6/1/2017.

9/2016	BCBSA National medical policy review. New investigational indications described. Clarified coding information. Effective 9/1/2016
6/2016	Clarified coding information.
1/2016	Clarified coding information.
6/2015	BCBSA National medical policy review. New investigational indications described. Effective 6/1/2015.
2/2015	Prior authorization clarified for CPT codes 63650 and 63685. Clarified coding information.
6/2014	Updated Coding section with ICD10 procedure and diagnosis codes, effective 10/2015.
6/2014	BCBSA National medical policy review. New investigational indications described; existing investigational statement modified to state all other situations. Effective 6/1/2014.
12/2013	Removed HCPCS codes C1767, C1816, L8680, and L8682-L8688 as they do not meet the intent of the policy.
10/2013	Removed CPT codes 63661, 63662, 63663, 63664, 63688 and diagnosis codes 337.20 and 722.80 as they do not apply to the policy.
2/2013	New references from BCBSA National medical policy.
11/2011-4/2012	Medical policy ICD 10 remediation: Formatting, editing and coding updates. No changes to policy statements.
4/2011	BCBSA National medical policy review. No changes to policy statements.
1/2011	Reviewed - Medical Policy Group - Neurology and Neurosurgery. No changes to policy statements.
4/2010	BCSBA National medical policy review. Changes to policy statements.
1/2010	Reviewed - Medical Policy Group - Neurology and Neurosurgery. No changes to policy statements.
1/2009	Reviewed - Medical Policy Group - Neurology and Neurosurgery. No changes to policy statements.
11/2008	Policy 083 effective 11/2008 stating covered and non-covered indications.
1/2008	BCBSA National medical policy review. No changes to policy statements.
1/2008	Reviewed - Medical Policy Group - Neurology and Neurosurgery. No changes to policy statements.
7/2007	Reviewed - Medical Policy Group - Neurology and Neurosurgery. No changes to policy statements.
4/2007	BCBSA National medical policy review. No changes to policy statements.
2/2007	Reviewed - Medical Policy Group - Psychiatry and Ophthalmology. No changes to policy statements.
1/2007	Reviewed - Medical Policy Group - Neurology and Neurosurgery. No changes to policy statements.

## Information Pertaining to All Blue Cross Blue Shield Medical Policies

Click on any of the following terms to access the relevant information:

[Medical Policy Terms of Use](#)

[Managed Care Guidelines](#)

[Indemnity/PPO Guidelines](#)

[Clinical Exception Process](#)

[Medical Technology Assessment Guidelines](#)

## References

1. Eldabe, SS, Buchser, EE, Duarte, RR. Complications of Spinal Cord Stimulation and Peripheral Nerve Stimulation Techniques: A Review of the Literature. Pain Med, 2016 Jan 28;17(2). PMID 26814260
2. Sivanesan, EE, Bicket, MM, Cohen, SS. Retrospective analysis of complications associated with dorsal root ganglion stimulation for pain relief in the FDA MAUDE database. Reg Anesth Pain Med, 2019 Jan 15;44(1). PMID 30640660

3. Turk DC, Dworkin RH, Allen RR, et al. Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. *Pain*. Dec 2003;106(3):337-345. PMID 14659516
4. Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. *Pain*. Jan 2005;113(1-2):9-19. PMID 15621359
5. Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. *J Pain*. Feb 2008;9(2):105-121. PMID 18055266
6. Kerns RD, Turk DC, Rudy TE. The West Haven-Yale Multidimensional Pain Inventory (WHYMPI). *Pain*. Dec 1985;23(4):345-356. PMID 4088697
7. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. *Ann Acad Med Singapore*. Mar 1994;23(2):129-138. PMID 8080219
8. Fairbank JC, Pynsent PB. The Oswestry Disability Index. *Spine (Phila Pa 1976)*. Nov 15 2000;25(22):2940-2952; discussion 2952. PMID 11074683
9. Ostelo RW, Deyo RA, Stratford P, et al. Interpreting change scores for pain and functional status in low back pain: towards international consensus regarding minimal important change. *Spine (Phila Pa 1976)*. Jan 1 2008;33(1):90-94. PMID 18165753
10. Wells GA, Tugwell P, Kraag GR, et al. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. *J Rheumatol*. Mar 1993;20(3):557-560. PMID 8478873
11. Kosinski M, Zhao SZ, Dedhiya S, et al. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. *Arthritis Rheum*. Jul 2000;43(7):1478-1487. PMID 10902749
12. Angst F, Aeschlimann A, Stucki G. Smallest detectable and minimal clinically important differences of rehabilitation intervention with their implications for required sample sizes using WOMAC and SF-36 quality of life measurement instruments in patients with osteoarthritis of the lower extremities. *Arthritis Rheum*. Aug 2001;45(4):384-391. PMID 11501727
13. Beck ATS, R.A. Beck Depression Inventory. San Antonio, TX: Psychological Corporation; 1993.
14. Curran SL, Andrykowski MA, Studts JL. Short Form of the Profile of Mood States (POMS-SF): Psychometric information. *Psychol Assess* 1995;7:80-83.
15. Visnjevac O, Costandi S, Patel BA, et al. A comprehensive outcome-specific review of the use of spinal cord stimulation for complex regional pain syndrome. *Pain Pract*. Apr 2017;17(4):533-545. PMID 27739179
16. O'Connell NE, Wand BM, McAuley J, et al. Interventions for treating pain and disability in adults with complex regional pain syndrome. *Cochrane Database Syst Rev*. Apr 30 2013(4):CD009416. PMID 23633371
17. Grider JS, Manchikanti L, Carayannopoulos A, et al. Effectiveness of spinal cord stimulation in chronic spinal pain: a systematic review. *Pain Physician*. Jan 2016;19(1):E33-54. PMID 26752493
18. Kapural L, Peterson E, Provenzano DA, et al. Clinical evidence for spinal cord stimulation for failed back surgery syndrome (FBSS): systematic review. *Spine (Phila Pa 1976)*. Jul 15 2017;42 Suppl 14:S61-S66. PMID 28441313
19. Frey ME, Manchikanti L, Benyamin RM, et al. Spinal cord stimulation for patients with failed back surgery syndrome: a systematic review. *Pain Physician*. Mar-Apr 2009;12(2):379-397. PMID 19305486
20. Head J, Mazza J, Sabourin V, et al. Waves of Pain Relief: A Systematic Review of Clinical Trials in Spinal Cord Stimulation Waveforms for the Treatment of Chronic Neuropathic Low Back and Leg Pain. *World Neurosurg*. Nov 2019;131:264-274.e3. PMID 31369885
21. North RB, Kidd DH, Farrokhi F, et al. Spinal cord stimulation versus repeated lumbosacral spine surgery for chronic pain: a randomized, controlled trial. *Neurosurgery*. Dec 2005;56(1):98-106; discussion 106-107. PMID 15617591
22. Kumar K, Taylor RS, Jacques L, et al. Spinal cord stimulation versus conventional medical management for neuropathic pain: a multicentre randomised controlled trial in patients with failed back surgery syndrome. *Pain*. Nov 2007;132(1-2):179-188. PMID 17845835
23. Perruchoud C, Eldabe S, Batterham AM, et al. Analgesic efficacy of high-frequency spinal cord stimulation: a randomized double-blind placebo-controlled study. *Neuromodulation*. Jul-Aug 2013;16(4):363-369; discussion 369. PMID 23425338
24. Kapural L, Yu C, Doust MW, et al. Novel 10-kHz High-frequency Therapy (HF10 Therapy) is superior to traditional low-frequency spinal cord stimulation for the treatment of chronic back and leg pain: the SENZA-RCT randomized controlled trial. *Anesthesiology*. Oct 2015;123(4):851-860. PMID 26218762



25. De Andres J, Monsalve-Dolz V, Fabregat-Cid G, et al. Prospective, randomized blind effect-on-outcome study of conventional vs high-frequency spinal cord stimulation in patients with pain and disability due to failed back surgery syndrome. *Pain Med.* Dec 1 2017;18(12):2401-2421. PMID 29126228
26. Simpson EL, Duenas A, Holmes MW, et al. Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin: systematic review and economic evaluation. *Health Technol Assess.* Mar 2009;13(17):iii, ix-x, 1-154. PMID 19331797
27. National Institute for Health and Care Excellence (NICE). Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin [TA159]. 2008; <https://www.nice.org.uk/guidance/ta159>. Accessed March 2, 2020.
28. Kemler MA, Barendse GA, van Kleef M, et al. Spinal cord stimulation in patients with chronic reflex sympathetic dystrophy. *N Engl J Med.* Aug 31 2000;343(9):618-624. PMID 10965008
29. Kemler MA, De Vet HC, Barendse GA, et al. The effect of spinal cord stimulation in patients with chronic reflex sympathetic dystrophy: two years' follow-up of the randomized controlled trial. *Ann Neurol.* Jan 2004;55(1):13-18. PMID 14705107
30. Slangen R, Schaper NC, Faber CG, et al. Spinal cord stimulation and pain relief in painful diabetic peripheral neuropathy: a prospective two-center randomized controlled trial. *Diabetes Care.* Nov 2014;37(11):3016-3024. PMID 25216508
31. Kumar K, Taylor RS, Jacques L, et al. The effects of spinal cord stimulation in neuropathic pain are sustained: a 24-month follow-up of the prospective randomized controlled multicenter trial of the effectiveness of spinal cord stimulation. *Neurosurgery.* Oct 2008;63(4):762-770; discussion 770. PMID 18981888
32. Kemler MA, de Vet HC, Barendse GA, et al. Effect of spinal cord stimulation for chronic complex regional pain syndrome Type I: five-year final follow-up of patients in a randomized controlled trial. *J Neurosurg.* Feb 2008;108(2):292-298. PMID 18240925
33. de Vos CC, Meier K, Zaalberg PB, et al. Spinal cord stimulation in patients with painful diabetic neuropathy: a multicentre randomized clinical trial. *Pain.* Nov 2014;155(11):2426-2431. PMID 25180016
34. Duarte RV, Andronis L, Lenders MW, et al. Quality of life increases in patients with painful diabetic neuropathy following treatment with spinal cord stimulation. *Qual Life Res.* Jul 2016;25(7):1771-1777. PMID 26694963
35. Rigoard, PP, Basu, SS, Desai, MM, Taylor, RR, Annemans, LL, Tan, YY, Johnson, MM, Van den Abeele, CC, North, RR. Multicolumn Spinal Cord Stimulation for Predominant Back Pain in Failed Back Surgery Syndrome Patients: A Multicenter Randomized Controlled Trial. *Pain*, 2019 Feb 6. PMID 30720582
36. Bicket MC, Dunn RY, Ahmed SU. High-frequency spinal cord stimulation for chronic pain: pre-clinical overview and systematic review of controlled trials. *Pain Med.* Dec 2016;17(12):2326-2336. PMID 28025366
37. Kapural L, Yu C, Doust MW, et al. Comparison of 10-kHz high-frequency and traditional low-frequency spinal cord stimulation for the treatment of chronic back and leg pain: 24-month results from a multicenter, randomized, controlled pivotal trial. *Neurosurgery.* Nov 2016;79(5):667-677. PMID 27584814
38. Al-Kaisy A, Palmisani S, Smith TE, et al. Long-term improvements in chronic axial low back pain patients without previous spinal surgery: a cohort analysis of 10-kHz high-frequency spinal cord stimulation over 36 months. *Pain Med.* Oct 24 2017. PMID 29077889
39. Hou S, Kemp K, Grabois M. A systematic evaluation of burst spinal cord stimulation for chronic back and limb pain. *Neuromodulation.* Jun 2016;19(4):398-405. PMID 27139915
40. De Ridder D, Plazier M, Kamerling N, et al. Burst spinal cord stimulation for limb and back pain. *World Neurosurg.* Nov 2013;80(5):642-649.e641. PMID 23321375
41. De Ridder D, Vanneste S, Plazier M, et al. Burst spinal cord stimulation: toward paresthesia-free pain suppression. *Neurosurgery.* May 2010;66(5):986-990. PMID 20404705
42. Schu S, Sloty PJ, Bara G, et al. A prospective, randomised, double-blind, placebo-controlled study to examine the effectiveness of burst spinal cord stimulation patterns for the treatment of failed back surgery syndrome. *Neuromodulation.* Jul 2014;17(5):443-450. PMID 24945621
43. Kriek N, Groeneweg JG, Stronks DL, et al. Preferred frequencies and waveforms for spinal cord stimulation in patients with complex regional pain syndrome: A multicentre, double-blind, randomized and placebo-controlled crossover trial. *Eur J Pain.* Mar 2017;21(3):507-519. PMID 27714945

44. Deer T, Slavin KV, Amirdelfan K, et al. Success Using Neuromodulation With BURST (SUNBURST) Study: results from a prospective, randomized controlled trial using a novel burst waveform. *Neuromodulation*. Jan 2018;21(1):56-66. PMID 28961366
45. Chang Chien GC, Mekhail N. Alternate intraspinal targets for spinal cord stimulation: a systematic review. *Neuromodulation*. Oct 2017;20(7):629-641. PMID 28160397
46. Vuka, II, Marciu, TT, Doenovi, SS, Ferhatovi Hamzi, LL, Vui, KK, Sapunar, DD, Puljak, LL. Neuromodulation with electrical field stimulation of dorsal root ganglion in various pain syndromes: a systematic review with focus on participant selection. *J Pain Res*, 2019 Mar 19;12:803-830. PMID 30881093
47. Huygen FJPM, Kallewaard JW, Nijhuis H, et al. Effectiveness and Safety of Dorsal Root Ganglion Stimulation for the Treatment of Chronic Pain: A Pooled Analysis. *Neuromodulation*. Feb 2020;23(2):213-221. PMID 31730273
48. Deer TR, Levy RM, Kramer J, et al. Dorsal root ganglion stimulation yielded higher treatment success rate for complex regional pain syndrome and causalgia at 3 and 12 months: a randomized comparative trial. *Pain*. Apr 2017;158(4):669-681. PMID 28030470
49. Food and Drug Administration. Summary of Safety and Effectiveness Data (SSED): Axium Neurostimulator System. 2016; [https://www.accessdata.fda.gov/cdrh\\_docs/pdf15/P150004b.pdf](https://www.accessdata.fda.gov/cdrh_docs/pdf15/P150004b.pdf). Accessed March 2, 2020.
50. Mekhail, NN, Deer, TT, Kramer, JJ, Poree, LL, Amirdelfan, KK, Grigsby, EE, Staats, PP, Burton, AA, Burgher, AA, Scowcroft, JJ, Golovac, SS, Kapural, LL, Paicius, RR, Pope, JJ, Samuel, SS, McRoberts, WW, Schaufele, MM, Kent, AA, Raza, AA, Levy, RR. Paresthesia-Free Dorsal Root Ganglion Stimulation: An ACCURATE Study Sub-Analysis. *Neuromodulation*, 2019 Mar 13. PMID 30861286
51. Schu S, Gulve A, EIDabe S, et al. Spinal cord stimulation of the dorsal root ganglion for groin pain-a retrospective review. *Pain Pract*. Apr 2015;15(4):293-299. PMID 24690212
52. Liem L, Russo M, Huygen FJ, et al. One-year outcomes of spinal cord stimulation of the dorsal root ganglion in the treatment of chronic neuropathic pain. *Neuromodulation*. Jan 2015;18(1):41-48; discussion 48-49. PMID 25145467
53. Huygen, FF, Liem, LL, Nijhuis, HH, Cusack, WW, Kramer, JJ. Evaluating Dorsal Root Ganglion Stimulation in a Prospective Dutch Cohort. *Neuromodulation*, 2018 Aug 7;22(1). PMID 30079622
54. Morgalla, MM, Fortunato, MM, Lepski, GG, Chander, BB. Dorsal Root Ganglion Stimulation (DRGS) for the Treatment of Chronic Neuropathic Pain: A Single-Center Study with Long-Term Prospective Results in 62 Cases.. *Pain Physician*, 2018 Jul 27;21(4). PMID 30045604
55. Eldabe, SS, Espinet, AA, Wahlstedt, AA, Kang, PP, Liem, LL, Patel, NN, Vesper, JJ, Kimber, AA, Cusack, WW, Kramer, JJ. Retrospective Case Series on the Treatment of Painful Diabetic Peripheral Neuropathy With Dorsal Root Ganglion Stimulation. *Neuromodulation*, 2018 Mar 27;21(8). PMID 29575331
56. Kallewaard, JJ, Nijhuis, HH, Huygen, FF, Wille, FF, Zuidema, XX, van de Minkelis, JJ, Raza, AA. Prospective Cohort Analysis of DRG Stimulation for Failed Back Surgery Syndrome Pain Following Lumbar Discectomy.. *Pain Pract*, 2018 Oct 1;19(2). PMID 30269439
57. Piedade, GG, Vesper, JJ, Chatzikalfas, AA, Sloty, PP. Cervical and High-Thoracic Dorsal Root Ganglion Stimulation in Chronic Neuropathic Pain. *Neuromodulation*, 2019 Jan 9. PMID 30620789
58. Kallewaard, JJ, Edelbroek, CC, Terheggen, MM, Raza, AA, Geurts, JJ. A Prospective Study of Dorsal Root Ganglion Stimulation for Non-Operated Discogenic Low Back Pain. *Neuromodulation*, 2019 Mar 2. PMID 30821901
59. Deer, TT, Pope, JJ, Hunter, CC, Falowski, SS, Kapural, LL, Kramer, JJ, Levy, RR. Safety Analysis of Dorsal Root Ganglion Stimulation in the Treatment of Chronic Pain. *Neuromodulation*, 2019 Mar 13. PMID 30861617
60. Weiner RL, Yeung A, Montes Garcia C, et al. Treatment of FBSS low back pain with a novel percutaneous DRG wireless stimulator: pilot and feasibility study. *Pain Med*. Oct 2016;17(10):1911-1916. PMID 27125284
61. Ubbink DT, Vermeulen H. Spinal cord stimulation for non-reconstructable chronic critical leg ischaemia. *Cochrane Database Syst Rev*. Feb 28 2013;2(2):CD004001. PMID 23450547
62. Klomp HM, Steyerberg EW, Habbema JD, et al. What is the evidence on efficacy of spinal cord stimulation in (subgroups of) patients with critical limb ischemia? *Ann Vasc Surg*. May-Jun 2009;23(3):355-363. PMID 19128928

63. Klomp HM, Spincemaille GH, Steyerberg EW, et al. Spinal-cord stimulation in critical limb ischaemia: a randomised trial. ESES Study Group. *Lancet*. Mar 27 1999;353(9158):1040-1044. PMID 10199350
64. Abu Dabrh AM, Steffen MW, Asi N, et al. Nonrevascularization-based treatments in patients with severe or critical limb ischemia. *J Vasc Surg*. Nov 2015;62(5):1330-1339 e1313. PMID 26409842
65. Pan X, Bao H, Si Y, et al. Spinal cord stimulation for refractory angina pectoris: a systematic review and meta-analysis. *Clin J Pain*. Jun 2017;33(6):543-551. PMID 27875377
66. Tsigaridas N, Naka K, Tsapogas P, et al. Spinal cord stimulation in refractory angina. A systematic review of randomized controlled trials. *Acta Cardiol*. Apr 2015;70(2):233-243. PMID 26148385
67. Zipes DP, Svorkdal N, Berman D, et al. Spinal cord stimulation therapy for patients with refractory angina who are not candidates for revascularization. *Neuromodulation*. Nov-Dec 2012;15(6):550-558; discussion 558-559. PMID 22494013
68. Lanza GA, Grimaldi R, Greco S, et al. Spinal cord stimulation for the treatment of refractory angina pectoris: a multicenter randomized single-blind study (the SCS-ITA trial). *Pain*. Jan 2011;152(1):45-52. PMID 21084162
69. Torre-Amione G, Alo K, Estep JD, et al. Spinal cord stimulation is safe and feasible in patients with advanced heart failure: early clinical experience. *Eur J Heart Fail*. Jul 2014;16(7):788-795. PMID 24961194
70. Zipes DP, Neuzil P, Theres H, et al. Determining the feasibility of spinal cord neuromodulation for the treatment of chronic systolic heart failure: The DEFEAT-HF Study. *JACC Heart Fail*. Feb 2016;4(2):129-136. PMID 26682789
71. Lihua P, Su M, Zejun Z, et al. Spinal cord stimulation for cancer-related pain in adults. *Cochrane Database Syst Rev*. Feb 28 2013;2(2):CD009389. PMID 23450600
72. Peng L, Min S, Zejun Z, et al. Spinal cord stimulation for cancer-related pain in adults. *Cochrane Database Syst Rev*. Jun 29 2015;6(6):CD009389. PMID 26121600
73. Mekhail NA, Mathews M, Nageeb F, et al. Retrospective review of 707 cases of spinal cord stimulation: indications and complications. *Pain Pract*. Mar-Apr 2011;11(2):148-153. PMID 21371254
74. Lanza GA, Barone L, Di Monaco A. Effect of spinal cord stimulation in patients with refractory angina: evidence from observational studies. *Neuromodulation*. Nov-Dec 2012;15(6):542-549; discussion 549. PMID 22364309
75. Dworkin RH, O'Connor AB, Kent J, et al. Interventional management of neuropathic pain: NeuPSIG recommendations. *Pain*. Nov 2013;154(11):2249-2261. PMID 23748119
76. Manchikanti L, Abdi S, Atluri S, et al. An update of comprehensive evidence-based guidelines for interventional techniques in chronic spinal pain. Part II: guidance and recommendations. *Pain Physician*. Apr 2013;16(2 Suppl):S49-283. PMID 23615883
77. Boswell MV, Trescot AM, Datta S, et al. Interventional techniques: evidence-based practice guidelines in the management of chronic spinal pain. *Pain Physician*. Jan 2007;10(1):7-111. PMID 17256025
78. Benzon, HH, Connis, RR, De Leon-Casasola, OO, Glass, DD, Korevaar, WW, Cynwyd, BB, Mekhail, NN, Merrill, DD, Nickinovich, DD, Rathmell, JJ, Sang, CC, Simon, DD. Practice guidelines for chronic pain management: an updated report by the American Society of Anesthesiologists Task Force on Chronic Pain Management and the American Society of Regional Anesthesia and Pain Medicine. *Anesthesiology*, 2010 Feb 4;112(4). PMID 20124882
79. Deer TR, Pope JE, Lamer TJ, et al. The Neuromodulation Appropriateness Consensus Committee on Best Practices for Dorsal Root Ganglion Stimulation. *Neuromodulation*. Jan 2019;22(1):1-35. PMID 30246899
80. Centers for Medicare and Medicaid Services. National Coverage Determination (NCD) for Electrical Nerve Stimulators (160.7). 1995; <https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=240&ncdver=1&bc=AAAAgAAAAAAA&>. Accessed March 2, 2020.